Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Jan 06, 2022

Wockhardt Approves Up To Rs 1,000-Crore Rights Issue

Wockhardt Approves Up To Rs 1,000-Crore Rights Issue
The Wockhardt Ltd. plant, a site used in the production of the AstraZeneca Plc and the University of Oxford Covid-19 vaccine, in Wrexham, U.K. (Photographer: Anthony Devlin/Bloomberg)

Wockhardt Ltd. approved a rights issue to raise funds for repaying debt.

The company's board approved issuance of equity shares worth up to Rs 1,000 crore to existing shareholders, according to its exchange filing. The objective of fundraising is to meet repayment of its subordinated debt which is due, funding research and development initiatives, and general corporate purposes.

The Mumbai-based drugmaker is yet to decide on the terms of the issue, including the rights entitlement ratio, the issue price, record date, and timing of the issue.

In February 2020, the company sold its domestic branded generics division comprising a portfolio of 62 products and a manufacturing facility at Baddi in Himachal Pradesh, to peer Dr. Reddy's Laboratories Ltd., which helped it pare debt.

BloombergQuint earlier reported that the company was looking to either sell more assets or get an equity partner.

The stock, trading 3% higher before the board approval was notified, pared some of the gains. It was trading 1.28% higher at 1.22 p.m. compared with 1.2% decline in S&P BSE Sensex.

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search